In this issue:
Movember raises funds for prostate cancer research
Australian Real World Cancer Evidence Network
177Lu-PSMA-617 + pembrolizumab promising for mCRPC
EMBARK: enzalutamide bests ADT in biochemically recurrent prostate cancer
RADICALS finds observation better than routine adjuvant radiotherapy
Phase 1 data for masofaniten + enzalutamide in mCRPC
Survival in advanced prostate cancer improved between 2008 and 2020
ARTO shows a benefit to adding SBRT in oligometastatic CRPC
ONCT-534 granted Fast Track status in the US
Hire A hubby supports pledge against prostate cancer
Hypofractionated radiotherapy use increases in the US
Pathogenic variants in range of DNA damage repair genes linked to aggressive disease
COVID-19 resources
Conferences & Workshops
Please login below to download this issue (PDF)